Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus

Monthly administration of anifrolumab resulted in a higher percentage of patients
with a response (as defined by a composite end point) at week 52 than did placebo,
in contrast to the findings of a similar phase 3 trial involving patients with SLE that
had a different primary end point. The frequency of herpes zoster was higher with
anifrolumab than with placebo.

Categorised in:

This post was written by admin